AR038483A1 - Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides - Google Patents
Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoidesInfo
- Publication number
- AR038483A1 AR038483A1 ARP030100347A ARP030100347A AR038483A1 AR 038483 A1 AR038483 A1 AR 038483A1 AR P030100347 A ARP030100347 A AR P030100347A AR P030100347 A ARP030100347 A AR P030100347A AR 038483 A1 AR038483 A1 AR 038483A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- cycloalkyl
- sor10
- so2r10
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 5
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000001931 aliphatic group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000006413 ring segment Chemical group 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Chemical group 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 206010067013 Normal tension glaucoma Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 239000000604 anti-edema agent Substances 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 229940121376 cannabinoid receptor agonist Drugs 0.000 abstract 1
- 239000003537 cannabinoid receptor agonist Substances 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000002978 low tension glaucoma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001328 optic nerve Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000050 smooth muscle relaxant Substances 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0202755A GB0202755D0 (en) | 2002-02-06 | 2002-02-06 | Organic compounds |
| GB0213285A GB0213285D0 (en) | 2002-06-10 | 2002-06-10 | Organic compound |
| GB0221459A GB0221459D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
| GB0221460A GB0221460D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038483A1 true AR038483A1 (es) | 2005-01-19 |
Family
ID=27739227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100347A AR038483A1 (es) | 2002-02-06 | 2003-02-04 | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20050085493A1 (https=) |
| EP (2) | EP1472234B1 (https=) |
| JP (2) | JP4428479B2 (https=) |
| KR (1) | KR100954626B1 (https=) |
| CN (1) | CN100579968C (https=) |
| AR (1) | AR038483A1 (https=) |
| AT (1) | ATE551329T1 (https=) |
| AU (1) | AU2003210212A1 (https=) |
| BR (1) | BR0307461A (https=) |
| CA (1) | CA2471974C (https=) |
| CO (1) | CO5601021A2 (https=) |
| EC (1) | ECSP045219A (https=) |
| ES (1) | ES2384967T3 (https=) |
| MX (1) | MXPA04007641A (https=) |
| MY (1) | MY143958A (https=) |
| NO (1) | NO328305B1 (https=) |
| NZ (1) | NZ571615A (https=) |
| PE (1) | PE20030867A1 (https=) |
| PL (1) | PL370657A1 (https=) |
| TW (1) | TW200306839A (https=) |
| WO (1) | WO2003066603A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2260007C2 (ru) | 1999-03-17 | 2005-09-10 | Астразенека Аб | Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| AU2004289638B2 (en) | 2003-11-04 | 2009-10-01 | Merck Sharp & Dohme Corp. | Substituted naphthyridinone derivatives |
| SE0303491D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
| CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
| GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
| US20090029984A1 (en) * | 2005-07-11 | 2009-01-29 | N.V. Organon | Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist) |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| FR2944013B1 (fr) * | 2009-04-07 | 2011-07-15 | Sanofi Aventis | Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique. |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
| CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
| CN106831502A (zh) * | 2017-03-13 | 2017-06-13 | 苏州市泽宸贸易有限公司 | 邻硝基苯磺酰氯、其合成方法及应用 |
| CN109796360B (zh) * | 2019-01-30 | 2022-03-18 | 上海阿拉丁生化科技股份有限公司 | 一种3-氨基-2-萘甲酸类化合物的制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6200M (https=) | 1967-04-18 | 1968-07-22 | ||
| DE1803210A1 (de) | 1968-10-16 | 1970-05-14 | Troponwerke Dinklage & Co | 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung |
| JPS5657768A (en) * | 1979-10-18 | 1981-05-20 | Masayuki Ishikawa | Novel 4-quinazolone derivative substituted by aromatic residue at 3-position |
| NZ192392A (en) * | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
| AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
| JPS57118570A (en) * | 1981-01-16 | 1982-07-23 | Masayuki Ishikawa | Novel 3-phenyl-4-quinazolone derivative |
| JPH07508030A (ja) * | 1992-05-13 | 1995-09-07 | アルコン ラボラトリーズ，インコーポレイテッド | カルシウムアンタゴニストと公知の抗緑内障薬との組合せを含む眼局所用組成物 |
| EP0887340A4 (en) | 1996-02-06 | 2000-03-29 | Japan Tobacco Inc | CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| TW200306839A (en) * | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| SE0303491D0 (sv) | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
| GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
-
2003
- 2003-01-30 TW TW092102105A patent/TW200306839A/zh unknown
- 2003-02-04 AR ARP030100347A patent/AR038483A1/es unknown
- 2003-02-04 PE PE2003000129A patent/PE20030867A1/es not_active Application Discontinuation
- 2003-02-05 MY MYPI20030387A patent/MY143958A/en unknown
- 2003-02-05 US US10/503,779 patent/US20050085493A1/en not_active Abandoned
- 2003-02-05 CN CN03803448A patent/CN100579968C/zh not_active Expired - Fee Related
- 2003-02-05 KR KR1020047012147A patent/KR100954626B1/ko not_active Expired - Fee Related
- 2003-02-05 EP EP03737316A patent/EP1472234B1/en not_active Expired - Lifetime
- 2003-02-05 BR BR0307461-7A patent/BR0307461A/pt active Search and Examination
- 2003-02-05 PL PL03370657A patent/PL370657A1/xx unknown
- 2003-02-05 EP EP10175740A patent/EP2319839A1/en not_active Withdrawn
- 2003-02-05 NZ NZ571615A patent/NZ571615A/en not_active IP Right Cessation
- 2003-02-05 AU AU2003210212A patent/AU2003210212A1/en not_active Abandoned
- 2003-02-05 JP JP2003565977A patent/JP4428479B2/ja not_active Expired - Fee Related
- 2003-02-05 ES ES03737316T patent/ES2384967T3/es not_active Expired - Lifetime
- 2003-02-05 WO PCT/EP2003/001140 patent/WO2003066603A1/en not_active Ceased
- 2003-02-05 CA CA2471974A patent/CA2471974C/en not_active Expired - Fee Related
- 2003-02-05 AT AT03737316T patent/ATE551329T1/de active
- 2003-02-05 MX MXPA04007641A patent/MXPA04007641A/es unknown
-
2004
- 2004-08-04 EC EC2004005219A patent/ECSP045219A/es unknown
- 2004-08-25 CO CO04083224A patent/CO5601021A2/es not_active Application Discontinuation
- 2004-08-27 NO NO20043580A patent/NO328305B1/no not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,315 patent/US8552015B2/en not_active Expired - Fee Related
-
2009
- 2009-01-22 JP JP2009012064A patent/JP2009149658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR100954626B1 (ko) | 2010-04-27 |
| CA2471974A1 (en) | 2003-08-14 |
| ECSP045219A (es) | 2004-09-28 |
| NO328305B1 (no) | 2010-01-25 |
| CA2471974C (en) | 2011-11-22 |
| JP2009149658A (ja) | 2009-07-09 |
| PL370657A1 (en) | 2005-05-30 |
| MXPA04007641A (es) | 2004-11-10 |
| EP2319839A1 (en) | 2011-05-11 |
| ATE551329T1 (de) | 2012-04-15 |
| BR0307461A (pt) | 2004-11-09 |
| PE20030867A1 (es) | 2003-12-04 |
| NO20043580D0 (no) | 2004-08-27 |
| HK1079518A1 (zh) | 2006-04-07 |
| US20070265285A1 (en) | 2007-11-15 |
| CN100579968C (zh) | 2010-01-13 |
| JP2005522439A (ja) | 2005-07-28 |
| WO2003066603A1 (en) | 2003-08-14 |
| ES2384967T3 (es) | 2012-07-16 |
| US20050085493A1 (en) | 2005-04-21 |
| EP1472234A1 (en) | 2004-11-03 |
| JP4428479B2 (ja) | 2010-03-10 |
| MY143958A (en) | 2011-07-29 |
| KR20040083501A (ko) | 2004-10-02 |
| NZ571615A (en) | 2010-01-29 |
| EP1472234B1 (en) | 2012-03-28 |
| TW200306839A (en) | 2003-12-01 |
| CO5601021A2 (es) | 2006-01-31 |
| NO20043580L (no) | 2004-09-21 |
| US8552015B2 (en) | 2013-10-08 |
| AU2003210212A1 (en) | 2003-09-02 |
| CN1628104A (zh) | 2005-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20090556A1 (es) | DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION | |
| MX2024003721A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| AR063211A1 (es) | Derivados de 3-(piridin-3-il)acrilamida y 3-(piridin-3-il)propionamida, un metodo para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con el receptor vaniloide. | |
| PE20130235A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| AR088218A1 (es) | Compuestos heterociclicos utiles como inhibidores de pi3k | |
| AR048315A1 (es) | Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas. | |
| UY39559A (es) | Compuestos y su uso | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
| DOP2006000125A (es) | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia | |
| PE20080378A1 (es) | Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| UY39517A (es) | Inhibidores de la btk | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| ECSP088257A (es) | Derivados de amida | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
| ECSP088602A (es) | Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| AR070603A1 (es) | Heterociclos de arilmetilideno 1,3 tiazolicos sustituidos,composiciones farmaceuticas que los contienen y usos de los mismos como agentes analgesicos, para prevenir y/o tratar el dolor y la inflamacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |